Corcept Therapeutics (CORT) Stock Price Declined While Timpani Capital Management Has Decreased Its Position; Blue Harbour Group LP Upped Its Commscope Hldg Co (COMM) Holding by $52.20 Million

CommScope Holding Company, Inc. (NASDAQ:COMM) Logo

Timpani Capital Management Llc decreased its stake in Corcept Therapeutics Inc (CORT) by 67.15% based on its latest 2018Q2 regulatory filing with the SEC. Timpani Capital Management Llc sold 164,711 shares as the company’s stock declined 25.98% while stock markets rallied. The institutional investor held 80,568 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $1.27 million, down from 245,279 at the end of the previous reported quarter. Timpani Capital Management Llc who had been investing in Corcept Therapeutics Inc for a number of months, seems to be less bullish one the $1.51B market cap company. It closed at $13.04 lastly. It is down 21.11% since December 8, 2017 and is downtrending. It has underperformed by 36.73% the S&P500. Some Historical CORT News: 15/03/2018 – CORCEPT THERAPEUTICS INC – FILED A LAWSUIT AGAINST TEVA FOR “INFRINGEMENT OF CORCEPT PATENTS” COVERING USE OF KORLYM(MIFEPRISTONE) 300 MG TABLETS; 14/05/2018 – Corcept Non-Deal Roadshow Scheduled By Seaport for May. 21; 15/03/2018 – CORCEPT SUIT ALLEGES INFRINGEMENT OF KORLYM PATENTS; 15/05/2018 – Corcept Closes Above 200-Day Moving Average: Technicals; 08/05/2018 – CORCEPT THERAPEUTICS INC CORT.O FY2018 REV VIEW $290.2 MLN — THOMSON REUTERS l/B/E/S; 23/04/2018 – DJ Corcept Therapeutics Incorporated, Inst Holders, 1Q 2018 (CORT); 14/03/2018 Corcept Rises for 7 Days; Tied for Longest Rally

Blue Harbour Group Lp increased its stake in Commscope Hldg Co Inc (COMM) by 23.26% based on its latest 2018Q2 regulatory filing with the SEC. Blue Harbour Group Lp bought 1.80M shares as the company’s stock rose 3.01% with the market. The hedge fund held 9.54M shares of the technology company at the end of 2018Q2, valued at $278.56 million, up from 7.74M at the end of the previous reported quarter. Blue Harbour Group Lp who had been investing in Commscope Hldg Co Inc for a number of months, seems to be bullish on the $3.25 billion market cap company. The stock decreased 3.26% or $0.57 during the last trading session, reaching $16.93. About 1.83M shares traded. CommScope Holding Company, Inc. (NASDAQ:COMM) has declined 8.63% since December 8, 2017 and is downtrending. It has underperformed by 24.25% the S&P500. Some Historical COMM News: 10/05/2018 – CommScope Upgrades Microwave Antenna Portfolio for Next Generation Wireless Backhaul; 16/05/2018 – CommScope Presenting at Bank of America Conference Jun 6; 01/05/2018 – COMMSCOPE SEES 2Q ADJ EPS 63C TO 68C, EST. 67C; 09/04/2018 – COMMSCOPE & CCI ENTER ANTENNA LICENSE PACTS SETTLE ALL PENDING; 09/04/2018 – CommScope and CCI Enter Antenna License Agreements, Settle All Pending Litigations; 26/04/2018 – CommScope Closes Below 50-Day Moving Average: Technicals; 15/05/2018 – CommScope Presenting at JPMorgan Conference Tomorrow; 01/05/2018 – CommScope Revised Outlook Primarily to Reflect Price Cuts at Certain Large North American Operators Expected in 2018 and 2019, as Well as Higher Input Costs; 01/05/2018 – CommScope Holding 1Q Net $33.7M; 01/05/2018 – CommScope Holding Sees 2Q EPS 31c-EPS 34c

Among 16 analysts covering CommScope Holding (NASDAQ:COMM), 7 have Buy rating, 0 Sell and 9 Hold. Therefore 44% are positive. CommScope Holding had 49 analyst reports since July 24, 2015 according to SRatingsIntel. Citigroup maintained CommScope Holding Company, Inc. (NASDAQ:COMM) on Wednesday, May 2 with “Buy” rating. On Tuesday, October 10 the stock rating was maintained by Jefferies with “Buy”. The company was maintained on Friday, March 9 by Citigroup. The stock has “Neutral” rating by Longbow on Friday, August 4. The rating was maintained by Barclays Capital with “Overweight” on Tuesday, November 10. Longbow downgraded the stock to “Neutral” rating in Friday, November 9 report. The stock of CommScope Holding Company, Inc. (NASDAQ:COMM) has “Equal-Weight” rating given on Tuesday, September 20 by Morgan Stanley. The stock has “Hold” rating by Northland Capital on Tuesday, August 8. The firm earned “Buy” rating on Thursday, February 15 by Jefferies. Northland Capital maintained the stock with “Hold” rating in Friday, February 16 report.

Investors sentiment decreased to 1.14 in Q2 2018. Its down 0.19, from 1.33 in 2018Q1. It dropped, as 46 investors sold COMM shares while 69 reduced holdings. 44 funds opened positions while 87 raised stakes. 193.46 million shares or 2.67% more from 188.43 million shares in 2018Q1 were reported. Metropolitan Life Insurance New York reported 0% of its portfolio in CommScope Holding Company, Inc. (NASDAQ:COMM). Clear Harbor Asset Mgmt Limited Liability Company has invested 0.43% of its portfolio in CommScope Holding Company, Inc. (NASDAQ:COMM). Fjarde Ap has 0.03% invested in CommScope Holding Company, Inc. (NASDAQ:COMM) for 68,826 shares. Wg Shaheen Dba Whitney Company accumulated 40 shares. Natixis Advsrs LP holds 141,702 shares or 0.04% of its portfolio. 79,738 were accumulated by Price T Rowe Associates Md. Poplar Forest Ltd Company, California-based fund reported 22,225 shares. Engineers Gate Manager Lp reported 0.02% in CommScope Holding Company, Inc. (NASDAQ:COMM). Meiji Yasuda Asset Mgmt Ltd holds 7,670 shares. Neuberger Berman Gp Limited holds 0.03% or 1.06M shares in its portfolio. Moreover, Earnest has 0% invested in CommScope Holding Company, Inc. (NASDAQ:COMM) for 49 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has 59,458 shares. 7.91 million are owned by Route One Lp. Lapides Asset Management Lc invested in 0.32% or 51,600 shares. Cannell Peter B And accumulated 0.33% or 305,174 shares.

More notable recent CommScope Holding Company, Inc. (NASDAQ:COMM) news were published by: Nasdaq.com which released: “Rexahn Pharmaceuticals Appoints Gil Price to its Board of Directors – Nasdaq” on December 03, 2018, also Nasdaq.com with their article: “Why Is CommScope (COMM) Down 13.5% Since Last Earnings Report? – Nasdaq” published on December 08, 2018, Nasdaq.com published: “This ETF Holds Stocks Insiders Want to Own – Nasdaq” on December 07, 2018. More interesting news about CommScope Holding Company, Inc. (NASDAQ:COMM) were released by: Nasdaq.com and their article: “November ETF Asset Report: Short-Term Bonds Top – Nasdaq” published on December 05, 2018 as well as Schaeffersresearch.com‘s news article titled: “Behind the Etsy Stock Short Squeeze – Schaeffers Research” with publication date: November 08, 2018.

Blue Harbour Group Lp, which manages about $2.20B and $2.47 billion US Long portfolio, decreased its stake in Investors Bancorp Inc New (NASDAQ:ISBC) by 673,800 shares to 28.91 million shares, valued at $369.74M in 2018Q2, according to the filing.

Timpani Capital Management Llc, which manages about $202.98M and $338.71 million US Long portfolio, upped its stake in Ligand Pharmaceuticals Inc Com (NASDAQ:LGND) by 6,562 shares to 28,861 shares, valued at $5.98 million in 2018Q2, according to the filing. It also increased its holding in Shotspotter Inc by 16,403 shares in the quarter, for a total of 145,188 shares, and has risen its stake in Collegium Pharmaceuticals.

Among 8 analysts covering Corcept Therapeutics (NASDAQ:CORT), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Corcept Therapeutics had 16 analyst reports since February 2, 2017 according to SRatingsIntel. As per Friday, September 8, the company rating was maintained by Piper Jaffray. Piper Jaffray maintained Corcept Therapeutics Incorporated (NASDAQ:CORT) rating on Thursday, August 24. Piper Jaffray has “Buy” rating and $18.0 target. The firm has “Buy” rating given on Friday, April 13 by Seaport Global. The firm has “Buy” rating given on Tuesday, June 19 by FBR Capital. The stock of Corcept Therapeutics Incorporated (NASDAQ:CORT) has “Buy” rating given on Monday, August 13 by FBR Capital. The company was maintained on Friday, November 3 by Stifel Nicolaus. FBR Capital initiated Corcept Therapeutics Incorporated (NASDAQ:CORT) rating on Thursday, March 8. FBR Capital has “Buy” rating and $30.0 target. The stock has “Buy” rating by FBR Capital on Tuesday, March 20. The rating was maintained by FBR Capital on Tuesday, June 12 with “Buy”. The firm has “Buy” rating given on Wednesday, October 11 by Piper Jaffray.

More notable recent Corcept Therapeutics Incorporated (NASDAQ:CORT) news were published by: Globenewswire.com which released: “Corcept Therapeutics Announces Third Quarter 2018 Financial Results and Provides Corporate Update – GlobeNewswire” on November 01, 2018, also Zacks.com with their article: “Options Traders Expect Huge Moves in Corcept Therapeutics (CORT) Stock – Zacks.com” published on June 29, 2018, Seekingalpha.com published: “Should You Buy Corcept Therapeutics Before Earnings? – Seeking Alpha” on July 23, 2018. More interesting news about Corcept Therapeutics Incorporated (NASDAQ:CORT) were released by: Nasdaq.com and their article: “Notable Wednesday Option Activity: CORT, ADBE, ZN – Nasdaq” published on August 01, 2018 as well as Globenewswire.com‘s news article titled: “Corcept Therapeutics Announces Positive Relacorilant Data at the 2018 American Society of Clinical Oncology Meeting – GlobeNewswire” with publication date: June 04, 2018.

Analysts await Corcept Therapeutics Incorporated (NASDAQ:CORT) to report earnings on February, 28. They expect $0.17 EPS, 0.00% or $0.00 from last year’s $0.17 per share. CORT’s profit will be $19.63M for 19.18 P/E if the $0.17 EPS becomes a reality. After $0.14 actual EPS reported by Corcept Therapeutics Incorporated for the previous quarter, Wall Street now forecasts 21.43% EPS growth.

Since June 7, 2018, it had 4 insider buys, and 4 sales for $4.85 million activity. On Thursday, June 7 the insider FISHMAN ROBERT S sold $145,826.

CommScope Holding Company, Inc. (NASDAQ:COMM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.